1. Home
  2. KEN vs CRSP Comparison

KEN vs CRSP Comparison

Compare KEN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kenon Holdings Ltd.

KEN

Kenon Holdings Ltd.

HOLD

Current Price

$81.91

Market Cap

4.2B

Sector

Utilities

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$57.93

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEN
CRSP
Founded
2014
2013
Country
Singapore
Switzerland
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.9B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
KEN
CRSP
Price
$81.91
$57.93
Analyst Decision
Buy
Analyst Count
0
17
Target Price
N/A
$70.29
AVG Volume (30 Days)
18.4K
1.4M
Earning Date
05-27-2026
05-05-2026
Dividend Yield
4.64%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$289,590,000.00
Revenue This Year
N/A
$807.72
Revenue Next Year
N/A
$172.52
P/E Ratio
$9.21
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$29.60
$33.03
52 Week High
$89.89
$78.48

Technical Indicators

Market Signals
Indicator
KEN
CRSP
Relative Strength Index (RSI) 48.49 65.20
Support Level $78.28 $51.64
Resistance Level $86.05 $60.63
Average True Range (ATR) 2.24 2.44
MACD -0.44 1.13
Stochastic Oscillator 23.20 89.02

Price Performance

Historical Comparison
KEN
CRSP

About KEN Kenon Holdings Ltd.

Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: